Details of Disease

General Information of Disease (ID: DISTVIQI)

• Disease Name: Bladder disease
• Synonyms: urinary bladder disorder; bladder disease; bladder disorder; disease or disorder of urinary bladder; urinary bladder disease or disorder; disorder of urinary bladder; urinary bladder disease; disease of urinary bladder
• Disease Class: GC01: Bladder disorder
• Definition: A disease involving the urinary bladder.
• Disease Hierarchy:
  DIS0HU8N: Urinary tract disease
  DISWD40R: Disease
  DISTVIQI: Bladder disease
• ICD Code:
  ICD-11: ICD-11: DC11-DC1Z
  ICD-10: ICD-10: K80-K87
  Expand ICD-11: 'DC1Z
  Expand ICD-10: 'K80-K87
• Disease Identifiers:
  MONDO ID: MONDO_0006026
  MESH ID: D001745
  UMLS CUI: C0005686
  MedGen ID: 2278
  SNOMED CT ID: 42643001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Indigotindisulfonate	DMV9KR5	Approved	Small molecular drug	[1]
Iocetamic acid	DMVM3Z0	Approved	Small molecular drug	[1]
Mitomycin	DMH0ZJE	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GI-248573	DMT6J1E	Terminated	NA	[3]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MCP-204	DM0RZDF	Investigative	NA	[4]
TD-4001	DMKR4U9	Investigative	NA	[5]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CHRM3	TTQ13Z5	moderate	Genetic Variation	[6]
FGF2	TTGKIED	Strong	Biomarker	[7]
INS	TTZOPHG	Strong	Therapeutic	[8]
RGS2	TTKB7T3	Strong	Therapeutic	[9]
RGS4	TTGTKX9	Strong	Therapeutic	[9]
SLC18A3	TTV8KWS	Strong	Biomarker	[10]
VIP	TTGTWLF	Strong	Biomarker	[11]

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MT3	OTVCZ7HI	Limited	Altered Expression	[12]
RASSF1	OTEZIPB7	Limited	Biomarker	[13]
TIMP3	OTDGQAD1	Limited	Biomarker	[13]
LRIG2	OTDUBLIH	Strong	Genetic Variation	[14]
RGS3	OTYG5OXI	Strong	Therapeutic	[9]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Mitomycin FDA Label
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008844)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
• [5] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [6] A homozygous missense variant in CHRM3 associated with familial urinary bladder disease.Clin Genet. 2019 Dec;96(6):515-520. doi: 10.1111/cge.13631. Epub 2019 Sep 11.
• [7] Expression of transforming growth factor beta1 gene, basic fibroblast growth factor gene and hydroxyproline in diabetes-induced bladder dysfunction in a rat model.Neurourol Urodyn. 2008;27(3):254-9. doi: 10.1002/nau.20489.
• [8] The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.Gen Pharmacol. 1991;22(2):305-11. doi: 10.1016/0306-3623(91)90454-e.
• [9] Identification of potential therapeutic targets in hypertension-associated bladder dysfunction.BJU Int. 2010 Mar;105(6):877-83. doi: 10.1111/j.1464-410X.2009.08809.x. Epub 2009 Aug 18.
• [10] Transient suppression of the vesicular acetylcholine transporter in urinary bladder pathways following spinal cord injury.Brain Res. 2007 Mar 16;1137(1):20-8. doi: 10.1016/j.brainres.2006.12.042. Epub 2006 Dec 21.
• [11] Expression of phosphorylated cAMP response element binding protein (p-CREB) in bladder afferent pathways in VIP-/- mice with cyclophosphamide (CYP)-induced cystitis.J Mol Neurosci. 2008 Nov;36(1-3):299-309. doi: 10.1007/s12031-008-9045-y. Epub 2008 Feb 26.
• [12] Metallothionein isoform 3 as a potential biomarker for human bladder cancer.Environ Health Perspect. 2000 May;108(5):413-8. doi: 10.1289/ehp.00108413.
• [13] Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infection.PLoS One. 2013;8(3):e59089. doi: 10.1371/journal.pone.0059089. Epub 2013 Mar 18.
• [14] LRIG2 mutations cause urofacial syndrome. Am J Hum Genet. 2013 Feb 7;92(2):259-64. doi: 10.1016/j.ajhg.2012.12.002. Epub 2013 Jan 11.